Market Research Logo

Meniere Disease - Pipeline Review, H1 2016

Meniere Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Meniere Disease - Pipeline Review, H1 2016’, provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Meniere Disease
The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Meniere Disease
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meniere Disease Overview
Therapeutics Development
Pipeline Products for Meniere Disease - Overview
Meniere Disease - Therapeutics under Development by Companies
Meniere Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Meniere Disease - Products under Development by Companies
Meniere Disease - Companies Involved in Therapeutics Development
Orbis Biosciences, Inc.
Otonomy, Inc.
Quark Pharmaceuticals, Inc.
Sound Pharmaceuticals, Inc.
Synphora AB
Meniere Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
betamethasone valerate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OR-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPHL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-1005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meniere Disease - Recent Pipeline Updates
Meniere Disease - Dormant Projects
Meniere Disease - Product Development Milestones
Featured News & Press Releases
Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease
Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease
May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease
Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients
Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease
Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study
Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease
Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Meniere Disease, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Meniere Disease - Pipeline by Orbis Biosciences, Inc., H1 2016
Meniere Disease - Pipeline by Otonomy, Inc., H1 2016
Meniere Disease - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
Meniere Disease - Pipeline by Sound Pharmaceuticals, Inc., H1 2016
Meniere Disease - Pipeline by Synphora AB, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Meniere Disease Therapeutics - Recent Pipeline Updates, H1 2016
Meniere Disease - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Meniere Disease, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report